MDCX - Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndro
MDCX - Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
Story updates
12:17:13 PM UTC
SquawkNews
MDCX Medicus Pharma receives FDA “study may proceed” letter for NDA-enabling registrational skinject® study in patients with gorlin syndrome
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.